BioPharm International
January 01, 2004
Columns and Departments
17
1
There are pressures on biopharma to grow up — and to grow up fast. Although we still hear references to its "infancy," I think we're well past that stage and already confronting the awkward — and sometimes painful — experience of adolescence.
January 01, 2004
Improving Operations
17
1
By implementing a comprehensive improvement program for its organizational and operational functions, one company increased capacity by more than 100% and 50% for two of its biopharmaceutical products.
January 01, 2004
Improving Operations
17
1
Quality assurance units are interwoven throughout the biopharmaceutical enterprise and provide support to sustain operations. Most importantly, they must have the capacity and leadership to adapt to change.
January 01, 2004
International BioMarket
17
1
In September 2003, Sweden's biotechnology sector recorded a striking achievement. Amgen, the world's largest biotechnology company, announced plans to acquire exclusive rights to Biovitrum's small-molecule enzyme inhibitors for the treatment of metabolic diseases.
January 01, 2004
Product Development
17
1
Molecular mimicry is a common, but undesirable, property of disease proteins. Sequence similarities between cancer proteins and self-proteins allow tumor cells to hide, thereby avoiding attack from the immune system. HIV uses the same evasive tactic.
January 01, 2004
Improving Operations
17
1
Training programs do not have to be complex to be successful. There are basic elements, however, that all must have to meet FDA requirements and ensure that employees have the knowledge and skills to maintain high quality standards.
January 01, 2004
Columns and Departments
17
1
Biopharmaceutical companies can access their suppliers? resources to reduce validation and compliance efforts.
January 01, 2004
Columns and Departments
17
1
New policies revise payment formulas and open the door to increased scrutiny of prices and effectiveness.
January 01, 2004
Columns and Departments
17
1
Competition from generic drugs is rising. How should investors react when a blockbuster drug goes off patent?